Nicotinergic agonists, selective for the α7 nAChR, have proven effective in reducing macrophage cytokine production and inflammation in animal models of pancreatitis, DSS-induced colitis, and intestinal ileus (reviewed a.o. in [61]). The gene discussed is CHRNA7; the disease is colitis.